Oruka Therapeutics (ORKA) Capital Expenditures Growth (1y) (2011 - 2026)
Oruka Therapeutics (ORKA) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 143.40% |
| 10 | Oruka Therapeutics | 949.16 Mn | 118.01 Mn | - | 461.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 461.54% |
| Mar 31, 2022 | -66.67% |
| Sep 30, 2021 | -133.33% |
| Jun 30, 2021 | -33.33% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2017 | 100.34% |
| Dec 31, 2016 | -244.06% |
| Jun 30, 2016 | 5,820.00% |
| Mar 31, 2016 | 250.00% |
| Dec 31, 2015 | 117.20% |
| Sep 30, 2015 | -99.55% |
| Dec 31, 2014 | 2,225.00% |
| Sep 30, 2014 | 3,963.64% |
| Dec 31, 2011 | 800.00% |